文献库搜索 | GeneLibs

Volckmar(Anna-Lena),Endris(Volker),Bozorgm... Diagn Pathol 0000-00-00

...ALK-positivity by IHC. Consequently, we diagnosed the case as ALK-positive rendering the patient eligible to crizotinib ...

Xiao(DeSheng),Lu(Can),Zhu(Wei),He(QiuYan),... Oncotarget 0000-00-00

...ALK (6.8%). However, 11.7% of the surgical specimens were EML4-ALK-positive, whereas the positive proportion in the smal...

Zaarour(Mazen),Nazha(Bassel),Weerasinghe(C... Expert Rev Anticancer Ther 0000-00-00

...ALK inhibitors in the elderly population remains scarce. In our review, we briefly discuss the current evidence of ALK i...

Kazandjian(Dickran),Blumenthal(Gideon M),L... Oncologist 0000-00-00

...ALK-positive mNSCLC trials. The most common (≥25%) adverse reactions and laboratory test abnormalities included vision d...

Simonelli(M),Zucali(P),Santoro(A),Thomas(M... Ann Oncol 0000-00-00

...ALK-1 function through ALK-1 pathway inhibition. Overall, treatment-related grade 3-4 AEs were reported in eight patient...

Heinig(Katja),Miya(Kazuhiro),Kamei(Tomonor... Bioanalysis 0000-00-00

...ALK) inhibitor for treatment of patients with ALK-positive non-small-cell lung cancer who have progressed on or are into...

Pietrantonio(Filippo),Oddo(Daniele),Gloghi... Cancer Discov 0000-00-00

...ALK-MET inhibitor crizotinib plus vemurafenib, thus switching to dual MET and BRAF blockade, with rapid and marked effec...

Pyo(Jung-Soo),Kang(Guhyun),Sohn(Jin Hee) Int J Biol Markers 0000-00-00

...ALK IHC and fluorescence in situ hybridization (FISH). The diagnostic accuracy of ALK IHC was analyzed based on ALK IHC ...

Zhang(Y F),Zhou(S Z),Cheng(X Y),Yi(B),Shan... Br J Dermatol 0000-00-00

...ALK)5.,Baicalein treatment significantly attenuated HPS formation and collagen deposition in a mechanical-load-induced m...

Putora(Paul M),Szentesi(Kinga),Glatzer(Mar... Oncol Res Treat 0000-00-00

...ALK+ tumours (15%, p = 0.002). Among EGFR/ALKwt tumours, 41% were central compared to 63% of ALK+ tumours (p = 0.235).,O...